acyclic retinoid

Open Access
Acyclic Retinoid Overcomes Vemurafenib Resistance in Melanoma Cells via Dual Inhibition of MAPK and PI3K/AKT/mTOR Pathways
YUI SUZUKI, SOICHIRO USUKI, MITSUAKI NISHIZAWA, NORIYOSHI TANAKA, YOSHITOMO SUHARA and ICHIRO YAJIMA

Anticancer Research June 2025, 45 (6) 2265-2278; DOI: https://doi.org/10.21873/anticanres.17601
Open Access
Acyclic Retinoid Inhibits the EGFR/AKT Signaling Pathway and Cancels Cisplatin-resistant Cell Characteristics
MAKITO MOTOYAMA, RYOTA SHIGEFUKU, NORIYOSHI TANAKA, MITSUAKI NISHIZAWA, KEIGO OSHIO, YOSHITOMO SUHARA and ICHIRO YAJIMA

Anticancer Research February 2025, 45 (2) 433-443; DOI: https://doi.org/10.21873/anticanres.17432
You have access
Acyclic Retinoid Combined With Tenascin-C-derived Peptide Reduces the Malignant Phenotype of Neuroblastoma Cells Through N-Myc Degradation
KAZUKI OTSUKA, MANABU SASADA, YU HIRANO, YUSUKE NOHARA, TAKUYA IYODA, YOSHIKAZU HIGAMI, HIROAKI KODAMA and FUMIO FUKAI

Anticancer Research July 2019, 39 (7) 3487-3492; DOI: https://doi.org/10.21873/anticanres.13494

Main menu